Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasisulam in Platinum-Resistant Ovarian Cancer
NCT00428610Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2007
- Primary completion
- Feb 2011
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of tasisulam in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Eli Lilly and Company. Started Feb 2007; status: completed.
02
Drugs
tasisulam
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00428610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00428610.